ARCHIVES

Zaltrap Economics 101: The Pricing And Repricing of an Expensive Drug

This article is from The Cancer Letter archive.

Vol. 38 No. 43 | November 16, 2012

Download PDF Visit The Full Archive

Related Articles

Straus asks to “Set Record Straight”

September 2, 1988

In Brief: Breakthrough Prize Awarded to 11 Scientists

March 8, 2013

Promising Areas Of Research Listed By NCAB Subcommittee

February 12, 1982

NCI Sponsors Session At ASCO On Clinical Grant Applications

May 3, 1991

Phase III Trial of Alimta, Avastin Combination Fails Endpoint to Improve Overall Survival

September 28, 2012

AACR Changes Its Logo— For The Fifth Time Since 2000

June 11, 2014